Navigation Links
MAP Pharmaceuticals Announces Pricing of Its Initial Public Offering
Date:10/5/2007

MOUNTAIN VIEW, Calif., Oct. 5 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. announced today that it has priced its initial public offering of 5,000,000 shares of common stock at a price of $12.00 per share. All shares are being offered by MAP Pharmaceuticals. In addition, MAP Pharmaceuticals has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares to cover over-allotments, if any. Merrill Lynch & Co. and Morgan Stanley & Co. Incorporated are joint book-running managers for the offering and Deutsche Bank Securities Inc. is co-lead manager for the offering. MAP Pharmaceuticals' common stock will trade on the NASDAQ Global Market under the symbol "MAPP."

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on October 4, 2007. Any offer or sale will be made only by means of a written prospectus forming part of the effective registration statement. Copies of the final prospectus relating to the offering may be obtained from: Merrill Lynch & Co., 4 World Financial Center, New York, New York 10080 or Morgan Stanley, Prospectus Department, 1585 Broadway, New York, New York 10036.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to their registration or qualification under the securities laws of any such state or jurisdiction.

About MAP Pharmaceuticals

Located in Mountain View, California, MAP Pharmaceuticals, Inc. uses proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. The Company has several proprietary product candidates in clinical development that address large market opportunities,
'/>"/>

SOURCE MAP Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Speaker announces business members of IT Task Force
4. Doyle announces technology tax credits for Berbee
5. Doyle announces new energy, global warming policies
6. Doyle announces $80M renewable energy strategy
7. GE announces first installation of Discovery VCT
8. UWM announces winners of RGI awards
9. Third Wave announces two senior management appointments
10. Mirus announces new method for making antibodies
11. Merge announces sofware updates, upcoming acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... La Jolla, CA (PRWEB) July 23, 2014 ... adipose stem cell therapy in the US aimed at ... today announced their newest clinical study for Parkinson’s disease. ... and efficacy of stem cell therapy are paramount when ... , This clinical study makes stem cell therapy accessible ...
(Date:7/23/2014)... July 23, 2014 ... of Trendlines Agtech , announced it has ... Israel,s leading agricultural thermoplastics applications companies. ... Valentis,s technology combines nanocrystalline cellulose (NCC), a biodegradable, ... additional nanoparticles to produce highly improved polymeric films. ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 DuPont Pioneer ... business as vice president of Agricultural Biotechnology (ABT), effective ... where he served most recently as president, chief executive ... and business leadership in the seed and crop protection ... Paul E. Schickler , president of DuPont Pioneer. ...
(Date:7/23/2014)... , July 23, 2014 /PRNewswire/ - BioAmber ... biotechnology company producing sustainable chemicals, today announced that the ... full their option to purchase an additional 420,000 ... price of $12.00 per share, less underwriting discounts ... underwritten public offering of 2,800,000 shares of common ...
Breaking Biology Technology:StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 3Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 3
... Md., Aug. 14 Martek Biosciences,Corporation announced that it ... fiscal 2007 on September 5, 2007, at approximately 4:00 ... p.m. EDT Martek,will hold a conference call to discuss ... investors. The call is expected to be approximately one,hour ...
... 14 /PRNewswire-FirstCall/ - Dragon Pharmaceutical Inc.,(TSX: DDD; OTCBB: DRUG; BBSE: DRP) ... 2007. Highlights of the Second Quarter, 2007, - ... the same period of 2006, and ... quarter 2007;, - Gross profit and gross ...
... 15 /PRNewswire-FirstCall/ - YM BioSciences Inc.,(AMEX: ... oncology company that identifies,develops and commercializes differentiated ... AG (Wedel, Germany), its European partner,for the ... has recruited the 40th and final patient ...
Cached Biology Technology:Martek to Announce Third Quarter 2007 Results on September 5, 2007 2Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007 2Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007 3ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB 2ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB 3ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB 4
(Date:7/22/2014)... UT Arlington computer science and engineering professor with an ... three-year National Science Foundation grant worth more than $600,000 ... the fruit fly., Heng Huang, an associate professor, will ... the UT Arlington Computer Science and Engineering department. Scientists ... because a large number of genes involved in fruit ...
(Date:7/22/2014)... be good for the average steak, but it seems ... to survive Alaska,s winter cold. , "Alaska wood frogs ... steak does in your freezer and the frog comes ... than the steak," said Don Larson, University of Alaska ... paper demonstrating that freeze tolerance in Alaska wood frogs ...
(Date:7/22/2014)... Researchers from the USC Schaeffer Center for Health ... governing antipsychotic drugs with increased incarceration rates for ... scrutiny over whether cutbacks in mental health actually ... account. , Some health plans require an extra ... ordered for patients. This step called prior ...
Breaking Biology News(10 mins):UT Arlington big data team wins $600,000 NSF grant to build gene expression database 2Alaska frogs reach record lows in extreme temperature survival 2Alaska frogs reach record lows in extreme temperature survival 3Are state Medicaid policies sentencing people with mental illnesses to prison? 2
... F. Harrington Professor Emeritus at the University of Delaware, ... Heck, 79, was honored alongside fellow researchers Akira Suzuki, ... Negishi, 75, of Purdue University, "for palladium-catalyzed cross couplings ... award. The Nobel Prize in Chemistry was announced ...
... National Science Foundation (NSF) grant to upgrade and expand ... Solar Array (OVSA) http://www.ovsa.njit.edu/ has been ... to help scientists better understand the nature of solar ... "Space weather incidents such as coronal mass ...
... State University finds that fish located near coal-fired power plants ... further away. The surprising finding appears to be linked to ... which unfortunately poses problems of its own. "We found ... from a coal-fired power plant had mercury levels more than ...
Cached Biology News:UD Professor Emeritus wins Nobel Prize in Chemistry 2$5 million NSF grant will upgrade and expand NJIT radio telescope array 2$5 million NSF grant will upgrade and expand NJIT radio telescope array 3Study: Fish near coal-fired power plants have lower levels of mercury 2
... Recognizes Nabeta2. The epitope ... present in any other known ... expected to work on human ... highly conserved (17/19 residues). Reactivity ...
Chicken polyclonal to HAGH ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to N terminal amino acids 110-260 of Human HAGH. Entrez GeneID: 3029 Swiss ...
Mouse monoclonal [SPM325] to Xanthine Oxidase, prediluted ( Abpromise for all tested applications). Antigen: C terminal 358 amino acid fragment of human xanthine oxidase. Entrez Gene ID: 749...
... for DNA isolation. Designed to ... 96 well plate adapters from Mo ... entire plate length (max capacity is ... used for soil, microorganisms, animal tissue, ...
Biology Products: